← Back to screener

Protagonist Therapeutics, Inc PTGX

Rank #2351 · Nasdaq · $9.3B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
22.7
P/E
-118.0
P/B
43.21
ROE
-36.6%
Op. Margin
-156.1%
Debt Ratio
32%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -118.0x, P/B 43.21x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -36.6%. Ranks in the top 88% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 32%. Ranks in the top 17% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 125.7% year over year. Ranks in the top 3% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2016–$-0.0B$-0.0B$-0.0B–-377
2017–$-0.0B$-0.0B$-0.0B–-51
2018$0.0B$-0.0B$-0.0B$-0.0B-162.8-157
2019–$-0.0B$-0.0B$0.1B–31
2020–$-0.0B$-0.0B$0.1B–62
2021$0.0B$-0.1B$-0.1B$0.1B-34857.640
2022$0.0B$-0.1B$-0.1B$0.1B-225.460
2023$0.0B$-0.1B$-0.1B$0.3B-460.012
2024$0.0B$-0.1B$-0.1B$0.3B-494.27
2025$0.1B$-0.1B$-0.1B$0.2B-156.132

← See the full screener